SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001157523-22-001698
Filing Date
2022-12-01
Accepted
2022-12-01 08:05:25
Documents
13
Period of Report
2022-12-01
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 ALDEYRA THERAPEUTICS, INC. 8-K a52993162.htm   iXBRL 8-K 33319
2 EXHIBIT 99.1 a52993162ex99_1.htm EX-99.1 15620
  Complete submission text file 0001157523-22-001698.txt   192511

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aldx-20221201.xsd EX-101.SCH 3920
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20221201_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20221201_pre.xml EX-101.PRE 16040
7 EXTRACTED XBRL INSTANCE DOCUMENT a52993162_htm.xml XML 4233
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 221437398
SIC: 2834 Pharmaceutical Preparations